がん治療用チェックポイント阻害薬の世界市場：CTLA-4阻害薬、PD-1阻害薬...市場調査レポートについてご紹介

1. Report Overview
1.1 Global Overview of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2015
1.2 Benefits of This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methods of the Study
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain

2. Introduction to the Checkpoint Inhibitor Anti-Cancer World Market 2015
2.1 Checkpoint Inhibitors: A New Era in Immunotherapy
2.2 Checkpoint Inhibitor Drug Treatments in Oncology

3. Leading Checkpoint Inhibitors: Anti-Cancer Drug Forecasts 2016-2026 and Leading Companies in the World Market
3.1 Leading Checkpoint Inhibitor Anti-Cancer Drug Treatments on the Market in 2015
3.1.1 Yervoy (ipilimumab) – Bristol-Myers Squibb
3.1.1.1 Yervoy: Sales Analysis
3.1.2 Opdivo (nivolumab) – Bristol-Myers Squibb/Ono Pharmaceutical
3.1.2.1 Opdivo: Sales Analysis
3.1.3 Keytruda (pembrolizumab) – Merck & Co.
3.1.3.1 Keytruda: Sales Analysis
3.2 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Treatment Market in 2015
3.2.1 Bristol-Myers Squibb Leads the Market

4. Checkpoint Inhibitor Anti-Cancer Treatment: World Market 2016-2026
4.1 The Global Market for Checkpoint Inhibitor Anti-Cancer Treatments in 2014
4.2 The World Anti-Cancer Checkpoint Inhibitor Market: Revenue Forecasts 2015-2026
4.3 Leading Checkpoint Inhibitor Treatment Submarkets Forecast 2016-2026
4.3.1 The CTLA-4 Inhibitors Submarket Forecast 2016-2026
4.3.2 The PD-1 Inhibitors Submarket Forecast 2016-2026
4.3.3 Changing Market Shares: PD-1 Inhibitors Will Lead the Market
4.3.4 Drivers and Restraints of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2016-2026
4.3.4.1 Drivers of the Checkpoint Inhibitor Anti-Cancer Treatment Market
4.3.4.2 Restraints of the Checkpoint Inhibitor Anti-Cancer Treatment Market

5. Leading National Markets for the Checkpoint Inhibitor Anti-Cancer Treatment Market 2016-2026
5.1 Regional Breakdown of the World Checkpoint Inhibitor Anti-Cancer Treatments Market 2014-2015
5.2 World Checkpoint Inhibitor Anti-Cancer Treatment Market: Regional Forecast 2016-2026
5.2.1 How Will Regional Market Shares Change to 2026?
5.3 The US Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.4 The EU Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.4.1 Germany: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.4.2 France: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.4.3 Italy: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.4.4 The UK: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.4.5 Spain: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.5 Japan: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.6 The APAC Market: Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026

6. The Checkpoint Inhibitor Anti-Cancer Treatment Market Pipeline Analysis 2016-2026
6.1 Anti-PD-1 Inhibitors and Anti-PD-L1 Inhibitors
6.1.1 Atezolizumab (MPDL3280A/RG7446) – Roche/Genentech
6.1.2 Durvalumab (MEDI4736) – AstraZeneca/MedImmune
6.1.3 Avelumab – (MSB0010718C) – Merck KGaA/Pfizer
6.1.4 Pidilizumab (CT-011) – CureTech Ltd
6.1.5 AMP-224 – GSK/Amplimmune
6.1.6 TSR-042 – TESARO Bio/AnaptysBio
6.1.7 AMP-514 (MEDI0680) – AstraZeneca/MedImmune
6.1.8 REGN2810 – Regeneron/Sanofi
6.2 CTLA-4 Inhibitors
6.2.1 Tremelimumab (CP-675,206) – AstraZeneca
6.3 LAG-3 (lymphocyte activation gene-3) Inhibitors
6.3.1 IMP321- Prima Biomed
6.3.2 BMS-986016 – Bristol-Myers Squibb
6.3.3 IMP701 – Prima BioMed/Novartis
6.4 KIR Inhibitors
6.4.1 Lirilumab (IPH2102/BMS-986015) – Innate Pharma/Bristol-Myers Squibb
6.5 Anti-NKG2A Inhibitors
6.5.1 IPH2201 – Innate Pharma/AstraZeneca/MedImmune
6.6 Other Checkpoint Inhibitors
6.6.1 VISTA Inhibitors
6.6.1.1 CA-170 – Curis/Aurigene
6.6.2 IDO and TDO Inhibitors
6.6.2.1 Indoximod (NLG-9189) – NewLink Genetics
6.6.2.2 NLG919 – NewLink Genetics
6.6.2.3 INCB024360 – Incyte/Roche
6.6.3 A2aR Inhibitors
6.6.3.1 HTL-1071 – AstraZeneca/Heptares
6.6.4 Future Areas of Pipeline Research

7. Qualitative Analysis of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2016-2026
7.1 SWOT Analysis of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2016-2026
7.2 Strengths and Weaknesses of the Checkpoint Inhibitor Anti-Cancer Treatment Market
7.2.1 A Novel Treatment Method that Harnesses the Immune System’s Vast Potential
7.2.2 Pricing of the Treatments Will Attract Companies
7.2.3 Cost of Treatment Will Restrain Market Access
7.2.4 Side Effects May Prohibit Growth
7.3 Opportunities and Threats for the Checkpoint Inhibitor Anti-Cancer Treatment Market
7.3.1 Biomarkers Pave the Way for Optimum Utility
7.3.2 Combination Therapies Are Achieving Superior Results
7.3.3 The Cost Burden of Expensive Drug Treatments on Healthcare Systems
7.3.4 Crowding of the Market With Similar Products

8. Research Interviews
8.1 Interview with Dr Nicolai Wagtmann, PhD, Chief Scientific Officer, Innate Pharma, Marseille, France
8.1.1 Innate Pharma’s Immunotherapy Portfolio
8.1.2 The Advantages and Mechanisms Used by Checkpoint Inhibitors
8.1.3 The Disadvantages of Checkpoint Inhibitors
8.2 Interview with Dr. Frédéric Triebel, CFO/CSO of Prima Biomed, Founder of Immutep
8.2.1 LAG-3 Inhibitors: An Upcoming Area of Checkpoint Inhibitor Research
8.2.2 Advantages and Disadvantages of LAG-3 Inhibitors on the Checkpoint Inhibitor Market
8.2.3 The Future Direction of the Checkpoint Inhibitor Market for Prima Biomed

9. Conclusions
9.1 The Global Checkpoint Inhibitor Anti-Cancer Treatment Market: Current World Outlook
9.1.1 Driver for Growth: A Robust and Innovative Pipeline for the Checkpoint Inhibitors Anti-Cancer Treatment Market to 2026
9.2 Leading National Markets for the Checkpoint Inhibitor Anti-Cancer Treatment Market 2016-2026: The US and EU Will Retain Their Lead
9.3 The Future of the Checkpoint Inhibitor Anti-Cancer Treatment Market